Adverse effects of GLP – 1 Receptor Agonists
DOI:
https://doi.org/10.12775/JEHS.2025.78.57774Keywords
type 2 diabetes, obesity, glucagon – like peptide – 1 receptor agonists, hypoglycemia, gastrointestinal adverse effects, nonarteritic anterior ischaemic optic neuropathyAbstract
Introduction and purpose
Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nausea, vomiting, diarrhoea, constipation and, less commonly, pancreatitis and cholelithiasis. In addition, a recent retrospective cohort study suggested a possible association between nonarteritic anterior ischaemic optic neuropathy (NAION) and the use of one of the GLP – 1 RAs, semaglutide. The aim of this article is to review the side effects associated with GLP – 1 RAs therapy.
References
1. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Mol. Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102.
2.Van Bloemendaal L., Ten Kulve J.S., la Fleur S.E., Ijzerman R.G., Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS. J. Endocrinol. 2014;221:T1–T16. doi: 10.1530/JOE-13-0414.
3.Taha M.B., Yahya T., Satish P., Laird R., Agatston A.S., Cainzos-Achirica M., Patel K.V., Nasir K. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Curr. Atheroscler. Rep. 2022 doi: 10.1007/s11883-022-01041-7.
4.Honigberg M.C., Chang L.S., McGuire D.K., Plutzky J., Aroda V.R., Vaduganathan M. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA Cardiol. 2020;5:1182–1190. doi: 10.1001/jamacardio.2020.1966.
5.Yin W.L., Bain S.C., Min T. The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. Diabetes Ther. 2020;11:835–844. doi: 10.1007/s13300-020-00798-x.
6.Sattar N., Lee M., Kristensen S.L., Branch K., Del Prato S., Khurmi N.S., Lam C., Lopes R.D., McMurray J., Pratley R.E., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–662. doi: 10.1016/S2213-8587(21)00203-5.
7.Aroda V.R., Ahmann A., Cariou B., Chow F., Davies M.J., Jódar E., Mehta R., Woo V., Lingvay I. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45:409–418. doi: 10.1016/j.diabet.2018.12.001.
8.Kushner R.F., Calanna S., Davies M., Dicker D., Garvey W.T., Goldman B., Lingvay I., Thomsen M., Wadden T.A., Wharton S., et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity Silver Spring. 2020;28:1050–1061. doi: 10.1002/oby.22794.
9.Aroda V.R., Bauer R., Christiansen E., Haluzík M., Kallenbach K., Montanya E., Rosenstock J., Meier J.J. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes Obes. Metab. 2022;24:1338–1350. doi: 10.1111/dom.14710.
10.Blonde L., Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: An overview of the LEAD 1-5 studies. Diabetes Obes. Metab. 2009;11((Suppl. 3)):26–34. doi: 10.1111/j.1463-1326.2009.01075.x.
11.Wharton S., Calanna S., Davies M., Dicker D., Goldman B., Lingvay I., Mosenzon O., Rubino D.M., Thomsen M., Wadden T.A., et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes. Metab. 2022;24:94–105. doi: 10.1111/dom.14551.
12.Tofé S., Argüelles I., Mena E., Serra G., Codina M., Urgeles J.R., García H., Pereg V. Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study. Endocrinol. Diabetes Metab. 2018;2:e00051. doi: 10.1002/edm2.51.
13.Tanaka K., Okada Y., Tokutsu A., Tanaka Y. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: A retrospective study. Sci. Rep. 2022;12:154. doi: 10.1038/s41598-021-04149-z.
14.Mody R., Yu M., Nepal B., Konig M., Grabner M. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data. Diabetes Obes. Metab. 2021;23:106–115. doi: 10.1111/dom.14195.
15.Mody R., Huang Q., Yu M., Zhao R., Patel H., Grabner M., Landó L.F. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes. Metab. 2019;21:920–929. doi: 10.1111/dom.13603.
16.Qiao Q., Ouwens M.J., Grandy S., Johnsson K., Kostev K. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab. Syndr. Obes. 2016;9:201–205. doi: 10.2147/DMSO.S99732.
17.Yu M., Xie J., Fernandez Lando L., Kabul S., Swindle R.W. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation. Clin. Ther. 2016;38:149–160. doi: 10.1016/j.clinthera.2015.11.017.
18.Domingo M. Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients’ selection from a multidisciplinary approach. Av. Diabetol. 2010;26:226–234. doi: 10.1016/S1134-3230(10)64003-3.
19.Holst J.J., Andersen D.B., Grunddal K.V. Actions of glucagon-like peptide-1 receptor ligands in the gut. Br. J. Pharmacol. 2022;179:727–742. doi: 10.1111/bph.15611.
20.Svensson A.M., Toll A., Lebrec J., Miftaraj M., Franzén S., Eliasson B. Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden. Diabetes Obes. Metab. 2021;23:720–729. doi: 10.1111/dom.14276.
21.Patel D., Smith A. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. Expert Rev. Clin. Pharmacol. 2021;14:1193–1204. doi: 10.1080/17512433.2021.1947796.
22.Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J. Clin. Pharm. Ther. 2020;45((Suppl. 1)):43–60. doi: 10.1111/jcpt.13225.
23.Steinberg W.M., Rosenstock J., Wadden T.A., Donsmark M., Jensen C.B., DeVries J.H. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants with Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data from the SCALE Clinical Development Program. Diabetes Care. 2017;40:839–848. doi: 10.2337/dc16-2684.
24.Marathe C.S., Rayner C.K., Jones K.L., Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp. Diabetes Res. 2011;2011:279530. doi: 10.1155/2011/279530.
25.Storgaard H., Cold F., Gluud L.L., Vilsbøll T., Knop F.K. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes. Metab. 2017;19:906–908. doi: 10.1111/dom.12885.
26.He L., Wang J., Ping F., Yang N., Huang J., Li Y., Xu L., Li W., Zhang H. Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern. Med. 2022;182:513–519. doi: 10.1001/jamainternmed.2022.0338.
27.Ayoub W.A., Kumar A.A., Naguib H.S., Taylor H.C. Exenatide-induced acute pancreatitis. Endocr. Pract. 2010;16:80–83. doi: 10.4158/EP09104.CRR.
28.Lingvay I., Hansen T., Macura S., Marre M., Nauck M.A., de la Rosa R., Woo V., Yildirim E., Wilding J. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res. Care. 2020;8:e001706. doi: 10.1136/bmjdrc-2020-001706.
29.Ellero C., Han J., Bhavsar S., Cirincione B.B., Deyoung M.B., Gray A.L., Yushmanova I., Anderson P.W. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: A retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. Diabet. Med. 2010;27:1168–1173. doi: 10.1111/j.1464-5491.2010.03085.x.
30.Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy. Eye (Lond) 2015;29:65–79.
31.Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol 2024:e242296.
32.Singh AK, Kesavadev J, Tiwaskar M. Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About? J Assoc Physicians India 2024;72(8):11–12.
33.Ard J., Cannon A., Lewis C.E., Lofton H., Vang Skjøth T., Stevenin B., Pi-Sunyer X. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: Subgroup analysis across the SCALE and phase II randomized trials. Diabetes Obes. Metab. 2016;18:430–435. doi: 10.1111/dom.12632.
34.Jendle J., Grunberger G., Blevins T., Giorgino F., Hietpas R.T., Botros F.T. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: A comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab. Res. Rev. 2016;32:776–790. doi: 10.1002/dmrr.2810.
35.Grimm M., Han J., Weaver C., Griffin P., Schulteis C.T., Dong H., Malloy J. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: An integrated analysis of the DURATION trials. Postgrad. Med. 2013;125:47–57. doi: 10.3810/pgm.2013.05.2660.
36.Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 2008;24:275–286. doi: 10.1185/030079908X253870.
37.Feng W., Wang W., Meng R., Wu G., Zhang M., Zhang X., Yin H., Zhu D. Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: A pooled analysis of data from the GetGoal Studies. BMJ Open Diabetes Res. Care. 2021;9:e002290. doi: 10.1136/bmjdrc-2021-002290.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 52
Number of citations: 0
